GlassScriptPhysician profile
Dipak Patel
NPI 1407849524
$2,146.94
in general payments reported to CMS, 2019-2025
24 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.96 · 2020: $91.82 · 2021: $92.04 · 2022: $463 · 2023: $434 · 2024: $647 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $473.69 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $413.28 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $232.57 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $133.31 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.96 | 2022-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $108.45 | 2022-2024 | |
| Abbvie INC. | $83.33 | 2021-2023 | |
| Pfizer INC. | $68.22 | 2022-2024 | |
| Amarin Pharma, INC. | $67.35 | 2019-2022 | |
| Abbott Laboratories | $54.66 | 2022-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.00 | 2020 | |
| Xeris Pharmaceuticals, INC. | $48.49 | 2023-2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $39.81 | 2025 | |
| Boston Scientific Corporation | $37.82 | 2024 | |
| Exact Sciences Corporation | $31.30 | 2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.05 | 2019-2020 | |
| Dexcom, INC. | $27.80 | 2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $22.74 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $19.48 | 2024 | Voquezna |
| Astellas Pharma US INC | $19.07 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $18.73 | 2023 | |
| Shield Therapeutics INC | $13.72 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $12.99 | 2022 | |
| Ibsa Pharma INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.